Teva makes changes to North American leadership, other executive management roles

Teva Pharmaceutical Industries Ltd., which has its U.S. headquarters in Parsippany, has made some changes to its executive leadership, including a new head of its North America commercial operations.

Brendan O’Grady, executive vice president, North America commercial, is leaving the Israel-based company to pursue another opportunity, Teva said in a news release, and will be replaced by Sven Dethlefs, Teva’s executive vice president, global marketing and portfolio and international markets commercial.

“On behalf of the Teva board of directors and our executive management team, I want to thank Brendan for his many contributions to Teva during his 30 years with the company,” CEO and President Kare Schultz said in a prepared statement. “Most recently, for his leadership in helping to stabilize the U.S. business and setting Teva up for future growth as head of North America commercial, during challenging times.

“I am pleased to announce the appointment of Sven Dethlefs to this critical role. Sven has been part of the executive management team since 2017, and held leadership roles in Teva’s global specialty business, commercial European business and in our global operations. I have every confidence that Sven will bring great strength to the regional business and the benefit of patients.”

To replace Dethlefs in his current role, Mark Sabag, the company’s chief human resources officer and head of communications, brand and environmental, social and governance, has been appointed EVP, international markets commercial, and Eli Shani, head of the global business development and alliance management group, will be promoted to EVP, global marketing and portfolio.

And Galia Inbar, senior vice president, global people operations, will be promoted to EVP, chief HR officer and head of global communications, brand and ESG, to replace Sabag.

“I am also proud to announce additional changes to our leadership team, which include the transition of Mark Sabag to lead the commercial business in our international markets, and the appointment of Galia Inbar and Eli Shani to lead our human resources, global communications, brand and ESG, and our global marketing and portfolio, respectively,” Schultz said. “These appointments demonstrate the quality and depth of our leadership bench, and I look forward to working closely with Sven, Mark, Galia, Eli and the rest of the team as we continue to lead Teva to meet its targets, implement its strategy and fulfill its mission.”

All changes will be effective Aug. 15, the company said.